A previous study showed that the PLK1 inhibitor volasertib could improve clinical outcomes in platinum‐resistant cancers.[8] To determine whether PLK1 activation is correlated with CRC progression after oxaliplatin based chemotherapy, we examined levels of PLK1 and p‐PLK1 in a set of CRC tissues from primary and relapse/metastasis samples (Figure 2G). This evidence concerns the gene PLK1 and cancer.